PROCEPT BioRobotics Notches Record Pricing But Procedure Growth Stalls as Self-Inflicted Sales Reorg Bites
Q1 2026 earnings call, April 29, 2026
PROCEPT BioRobotics delivered a quarter defined by contradiction: record capital equipment pricing and a gross margin recovery on one hand, and stalling procedure growth tied directly to management's own commercial reorganization on the other. Total revenue reached $83.1 million, up 20% year-over-year, but the print landed below some Street expectations, and the company's second-quarter guidance of $91 million to $95 million came in under the consensus $95 million, extending a run of disappointments that has left the stock down more than 62% over the past year.
Procedure Growth Decelerates as Sales Force Disruption Lingers
US procedures came in at approximately 12,200 for the quarter, up 30% year-over-year but essentially flat sequentially versus the fourth quarter of 2025 -- a deceleration that drew pointed questions from multiple analysts. CEO Larry Wood attributed the softness to normal Q1 seasonality combined with the disruption caused by finalizing a new integrated regional sales structure and a dedicated launch team model in early Q1. "We view this as a normal transition period as teams ramp, establish account relationships and standardize new operating processes," Wood said, while acknowledging "some short-term disruption in the first quarter." Management continues to guide to full-year procedure growth of 39% to 48%, implying a steep back-half acceleration that several analysts pressed on. Bank of America's Stephanie Piazzola specifically flagged that Q1 procedures grew 31% versus a full-year target near 50% in the second half, asking what underpins confidence in that ramp. Wood's answer leaned heavily on the maturation of newly launched systems under the launch team model and marketing pilots aimed at driving patient awareness, cautioning that "there's always just going to be a lag between driving patient awareness and a patient getting a procedure" given scheduling and workup timelines that can run a month or more.
Pricing Discipline Delivers, But Guidance Stays Conservative
The clearest bright spot in the quarter was pricing. US Hydros system average selling price hit $485,000, an all-time high and up 14% sequentially, despite a seasonally weak capital quarter for the industry. Handpiece ASP rose to roughly $3,500, up 10% year-over-year. Wood credited a deliberate shift toward "price discipline across the organization," extending to capital equipment the same approach previously applied to handpieces. Yet management chose not to raise full-year system pricing guidance to match the Q1 print, instead guiding to $450,000 to $460,000 for the remainder of the year -- which CFO Kevin Waters said implies a full-year average "more towards the upper end, probably around $460,000." Management was explicit about the reasoning: Q1 benefited from an absence of large IDN (integrated delivery network) orders, which tend to carry lower per-unit pricing than individual account sales. "We don't want to get out over our skis on ASP commitments," Wood said, a phrase he and Waters repeated multiple times through the call in response to analyst pressure to raise numbers. Waters added that confidence in the full-year systems guide "is higher today than it was when we gave guidance in February," but the company is holding formal guidance updates until mid-year.
Gross Margin Recovers to Guided Level After Q4 Stumble
Gross margin came in at 65% for the quarter, matching the full-year target and up sharply from 61% in the fourth quarter of 2025, which management had flagged as temporary. Waters attributed the improvement to pricing gains, cost discipline and favorable mix, and guided to modest sequential expansion of 10 to 20 basis points in Q2 and Q3, with an exit rate above 66% in the fourth quarter as handpiece mix improves and overhead absorption strengthens further. The company still expects $5 million to $6 million in tariff expense for 2026, up from $1.3 million in 2025, though potential tariff refunds not yet reflected in guidance could provide upside.
International Expansion Gains Early Traction in the UK
PROCEPT's first international Hydros launch, in the United Kingdom, showed early promise, with 7 systems sold in the quarter at an average selling price above $400,000 and what Wood described as "rapid adoption at high-volume NHS hospitals." International revenue grew 25% year-over-year to $11.1 million, continuing to outperform as a smaller but consistent growth contributor. Wood was careful to temper expectations for broader European expansion, noting that "international isn't a very homogeneous place" and that the company will selectively target markets with solid reimbursement rather than pursue a blanket rollout.
Clinical Guidelines Upgrade and WATER IV Trial Ahead of Schedule
In a meaningful clinical validation, the European Association of Urology upgraded its guidelines in March to give Aquablation therapy a strong recommendation for men with BPH and moderate-to-severe lower urinary tract symptoms, positioning it as an alternative to TURP particularly for patients seeking to preserve ejaculatory function. The company also received FDA clearance for its second-generation FirstAssist AI software, aimed at more precise prostate anatomy identification and treatment planning. Enrollment in the WATER IV prostate cancer trial is tracking ahead of schedule, with completion expected by the end of May 2026 in under 18 months -- a pace Wood called indicative of "strong surgical interest and a patient willingness to participate." Primary endpoint data is expected at AUA in spring 2027. Pressed by Oppenheimer's Suraj Kalia on whether a positive readout would generate symmetric benefits across BPH and prostate cancer indications, Wood declined to speculate on unreleased data but noted the adjacency requires no new capital equipment or handpieces, calling it "a perfect adjacency" that would leverage the existing sales force and installed base.
Replacement Cycle Begins, Reimbursement Concerns Muted
The AQUABEAM-to-Hydros replacement program logged its first 2 unit sales in the quarter, which Wood characterized as an encouraging start to what the company expects to become "a much bigger part of our story in 2027." On reimbursement, Wood pushed back against concerns tied to recent physician fee schedule changes affecting the procedure, stating flatly that "Medicare doesn't pay for value, they pay for resource consumption," and that the company has not built any potential APC (ambulatory payment classification) level changes into its guidance, framing any such change as pure upside rather than a risk factor.
Balance Sheet and Path to Profitability
Net loss widened to $31.6 million from $24.7 million a year ago, and adjusted EBITDA loss increased to $18.1 million from $15.8 million, reflecting higher operating expenses tied to commercial expansion and WATER IV funding. The company held $249 million in cash at quarter-end and reiterated its target of reaching positive adjusted EBITDA in the fourth quarter of 2026, with full-year adjusted EBITDA loss guided to a range of $17 million to $30 million.
PROCEPT BioRobotics Deep Dive: The AI-Powered Razor-and-Blade Model Disrupting Urology
The Business Model: Capitalizing on the Razor-and-Blade Strategy
PROCEPT BioRobotics operates a classic, high-margin installed-base medtech model, monetizing both capital equipment and recurring consumables. The company develops and commercializes robotic systems, historically the AQUABEAM and now the next-generation HYDROS platform, designed to perform Aquablation therapy for benign prostatic hyperplasia. The economic engine of the business relies on placing these capital-intensive robotic consoles in hospitals and ambulatory surgery centers, which then generate a predictable, recurring revenue stream through the sale of single-use handpieces and consumables tied to each procedure. In the first quarter of 2026, the company reported total revenue of $83.1 million, representing a 20% year-over-year increase. The unit economics are compelling: new HYDROS systems command an average selling price of approximately $485,000, while the single-use handpieces are priced around $3,500 each. With handpiece sales accounting for roughly 95% of the 12,200 procedures performed in the first quarter of 2026, the company is successfully driving high utilization rates across its installed base of 765 systems in the United States. This recurring revenue stream inherently insulates the company from the lumpiness of capital equipment cycles, creating a durable financial profile as the installed base matures.
Competitive Landscape and Market Share Dynamics
The surgical treatment market for benign prostatic hyperplasia is highly fragmented and dominated by entrenched legacy procedures, but PROCEPT BioRobotics is rapidly capturing market share. The primary competitors are not other robotic systems, but rather traditional transurethral resection of the prostate, laser enucleation procedures like HoLEP, and minimally invasive office-based devices such as Teleflex's UroLift and Boston Scientific's Rezum. Despite the prevalence of these alternatives, Aquablation is emerging as the new standard of care for larger prostates and complex anatomies. In 2024, Aquablation surpassed HoLEP in procedural volume, topping 33,000 procedures compared to HoLEP's 28,000. Yet, the runway for growth remains massive. The company currently holds only a 10% penetration rate in the 400,000 annual benign prostatic hyperplasia surgical procedures performed in the United States. Furthermore, there is a latent total addressable market of 8 million men relying on pharmaceutical therapies, of which over 1.1 million discontinue medication annually due to side effects or lack of efficacy. As legacy devices like UroLift face reimbursement pressures and declining adoption due to retreatment rates, PROCEPT BioRobotics is perfectly positioned to absorb this shifting market share, converting both drug-refractory patients and those who would have otherwise undergone traditional resective surgeries.
The Moat: Clinical Superiority and AI-Driven Automation
The competitive advantage of PROCEPT BioRobotics is rooted in the clinical superiority of its heat-free waterjet technology and the integration of artificial intelligence. Traditional resective surgeries and laser therapies rely on heat, which frequently damages surrounding nerves and tissues, leading to high rates of sexual and urinary dysfunction. Aquablation therapy mitigates this risk entirely. Recent clinical data from the WATER III trial demonstrated that patients undergoing Aquablation for large prostates experienced an ejaculatory dysfunction rate of just 14.8%, compared to a staggering 77.1% for those undergoing laser enucleation. This preservation of quality of life is a profound differentiator for patients and a powerful marketing tool for urologists. Furthermore, the company has widened its competitive moat with the launch of the HYDROS Robotic System, which received clearance in late 2024. HYDROS incorporates FirstAssist AI, an advanced image recognition software trained on over 50,000 real-world Aquablation procedures. This artificial intelligence overlay automatically identifies critical anatomy on ultrasound and suggests an optimal, patient-specific treatment plan. By automating the surgical planning phase and executing the resection robotically, PROCEPT BioRobotics has effectively standardized surgical outcomes, drastically reducing the learning curve for new urologists and eliminating the variability inherent in manual, surgeon-dependent procedures.
Industry Tailwinds and the Ambulatory Surgery Center Opportunity
The urology market is benefiting from powerful demographic tailwinds, primarily an aging male population that guarantees a steadily increasing incidence of benign prostatic hyperplasia. However, the most significant structural shift in the industry is the migration of surgical procedures from acute care hospitals to ambulatory surgery centers. These outpatient facilities can perform benign prostatic hyperplasia procedures at a 40% to 60% lower cost than hospital outpatient departments, offering same-day discharge and superior unit economics for providers. PROCEPT BioRobotics is aggressively targeting this shift. The company has optimized its clinical protocols to support same-day discharge and is leveraging the streamlined workflow of the HYDROS system to fit the high-throughput requirements of ambulatory surgery centers. Additionally, the regulatory environment has become highly favorable, with the Centers for Medicare and Medicaid Services assigning dedicated Category I CPT codes for Aquablation effective in 2026. This establishes a predictable and permanent reimbursement pathway, removing a critical friction point for facility adoption and incentivizing both hospitals and ambulatory surgery centers to invest in the capital equipment.
The Next Frontier: Disrupting the Prostate Cancer Market
While benign prostatic hyperplasia provides a robust and growing foundation, the most asymmetric upside for PROCEPT BioRobotics lies in its clinical pipeline for localized prostate cancer. The company is currently executing the WATER IV clinical program, a series of pivotal trials that could fundamentally disrupt the prostate cancer treatment paradigm. The first trial, which recently completed its 280-patient enrollment, is a randomized study comparing Aquablation directly against radical prostatectomy, the highly invasive standard of care that is notorious for causing permanent incontinence and erectile dysfunction. Furthermore, the company recently received an investigational device exemption to launch a second randomized trial comparing Aquablation against active surveillance for low-grade prostate cancer. If Aquablation can demonstrate oncologic efficacy while preserving urinary and sexual function, it will position the technology as a first-line intervention for millions of men who currently face the agonizing choice between the severe morbidity of a prostatectomy and the psychological burden of watchful waiting. Early procedures have already been successfully completed in ambulatory settings, signaling that PROCEPT BioRobotics is preparing to commercialize a highly scalable, outpatient-friendly prostate cancer treatment that could exponentially expand its total addressable market.
Management Track Record: The TAVR Playbook Comes to Urology
The strategic trajectory of PROCEPT BioRobotics is currently being orchestrated by Chief Executive Officer Larry Wood, who assumed the role in September 2025. Wood is a highly respected medtech veteran who spent decades at Edwards Lifesciences, where he was the architect behind the multi-billion-dollar transcatheter aortic valve replacement business. His track record of establishing a novel, disruptive technology as the global standard of care is exactly the playbook required for Aquablation. Since taking the helm, Wood has implemented a clinical and commercial realignment focused on operational excellence and disciplined pricing. In late 2025 and early 2026, management eliminated bulk purchase discounts for handpieces, prioritizing sustainable unit economics and higher-quality revenue over short-term volume metrics. Furthermore, Wood restructured the sales organization to include dedicated launch teams that focus exclusively on driving procedure utilization immediately after a system is installed. While this commercial reset caused minor near-term disruption, the first quarter 2026 results indicate that the strategy is already yielding improved pricing power and accelerating same-store procedure growth. The combination of a visionary medtech executive and a clinically superior product provides high confidence in the company's ability to execute its long-term market penetration strategy.
The Scorecard
PROCEPT BioRobotics represents a rare breed of medtech asset: a company with a clinically de-risked, commercially validated platform that is actively displacing entrenched legacy procedures in a massive, underserved market. The transition to the AI-powered HYDROS system solidifies the company's competitive moat by standardizing surgical outcomes and reducing physician learning curves, which is the ultimate catalyst for mass-market adoption. Furthermore, the razor-and-blade business model is currently hitting an inflection point, with high-margin consumable revenue scaling rapidly on the back of an expanding installed base of 765 domestic systems. The recent commercial realignment under a proven, world-class management team ensures that this top-line growth will be increasingly paired with disciplined unit economics and a clear pathway to profitability.
Beyond the core benign prostatic hyperplasia business, the optionality embedded in the WATER IV prostate cancer clinical program cannot be overstated. If the ongoing pivotal trials prove that Aquablation can deliver oncologic control without the devastating side effects of radical prostatectomy, PROCEPT BioRobotics will unlock a multi-billion-dollar total addressable market that completely redefines the company's valuation ceiling. Supported by favorable reimbursement dynamics, the ongoing shift to ambulatory surgery centers, and a demographic tailwind that guarantees steady patient volume, the company is uniquely positioned to become the undisputed standard of care in urologic surgery over the next decade.